P53 and ras gene mutations in lung cancer: Implications for smoking and occupational exposures

Journal of Occupational and Environmental Medicine

Volumn 37, Issue 1, 1995, Pages 69-76

  Husgafvel Pursiainen, Kirsti ^a   Ridanpää, Maaret ^a   Anttila, Sisko ^a   Vainio, Harri ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; PROTEIN P53; RADON;

CARCINOGENESIS; GENE MUTATION; HUMAN; LUNG CANCER; OCCUPATIONAL EXPOSURE; ONCOGENE RAS; REVIEW; SMOKING; TUMOR SUPPRESSOR GENE;

EPIDEMIOLOGY, MOLECULAR; GENES, P53; GENES, RAS; HUMAN; LUNG NEOPLASMS; MUTATION; OCCUPATIONAL EXPOSURE; PREVALENCE; SMOKING;

NICOTIANA TABACUM;

EID: 0028939528     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/00043764-199501000-00010     Document Type: Article

References (102)

1. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Tobacco Smoking. Vol. 38. Lyon: International Agency for Research on Cancer; 1986.
2. Doll R, Peto R. The Causes of Cancer. Quantitative Estimates of Avoidable Risks of Cancer in the United States Today. Oxford: Oxford University Press; 1981.
3. Bishop J. Molecular themes in oncogenesis. Cell. 1991;64:235-248.
4. Weinberg RA. Tumor suppressor genes. Science. 1991;254:1138-1146.
5. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem. 1993;62:851-891.
6. Bos, J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49:4682-4689.
7. Balmain A, Brown K. Oncogene activation in chemical carcinogenesis. Adv Cancer Res. 1988;51:147-182.
8. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
9. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-1327.
10. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994;69:409-416.
11. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70: 523-526.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
13. Thilly WG. Mutational spectrometry: opportunity and limitations in human risk assessment. In: Gamer RC, Farmer PB, Steel GT, Wright AS, eds. Human Carcinogen Exposure. Oxford: Oxford University Press; 1991:128-133.
14. Vogelstein B, Kinzler KW. Carcinogens leave fingerprints. Nature. 1992; 355:209-210.
15. Esteve A, Sørlie T, Martel-Planche G, et al. Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens. J Oc-cup Med. 1995;37(in press).
16. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350:427-428.
17. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350: 429-341.
18. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88:10124-10128.
19. Jones PA, Buckley JD, Henderson BE, et al. From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res. 1991;51:3617-3620.
20. Perera FP, Santella R. Carcinogenesis. In: Schulte PA, Perera FB, eds. Molecular Epidemiology. Principles and Practices. San Diego: Academic Press; 1993:277-300.
21. Sӧderkvist P, Axelson O. On the use of molecular biology data in occupational and environmental epidemiology. J Oc-cup Med. 1995;37(in press).
22. Ridanpää M, Karjalainen A, Anttila S, et al. Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. Int J Oncol. 1994; 5:1109-1117.
23. Testa JR, Siegfried JM. Chromosome abnormalities in human non-small cell lung cancer. Cancer Res. 1992;52: 2702s-2706s.
24. Minna JD. The molecular biology of lung cancer pathogenesis. Chest. 1993; 103(Suppl 4):449-456.
25. Rodenhuis S, Slebos RJC, Boot AJM, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738-5741.
26. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990; 323:561-565.
27. Mitsudomi T, Viallet J, Mulshine JL, et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6:1353-1362.
28. Suzuki Y, Orita M, Shiraishi M, et al. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1990;5:1037-1043.
29. Husgafvel-Pursiainen K, Hackman P, Ridanpää M, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer. 1993;53:250-256.
30. Fasano O, Aldrich T, Tamanoi F, et al. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci USA. 1984;81:4008-4012.
31. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 1992; 52:2665s-2669s.
32. Caron de Fromentel C, Soussi Th. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer. 1992;4: 1-15.
33. Tominaga O, Hamelin R, Remvikos Y, et al. p53 from basic research to clinical applications. Crit Rev Oncog. 1992; 3:257-282.
34. Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer. 1994;57:1-9.
35. Chiba I, Takahashi T, Naw MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene. 1990;5:1603-1610.
36. Takahashi T, Takahashi T, Suzuki H, et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 1991;6:1775-1778.
37. D’Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 1992;7:339-346.
38. Sameshima Y, Matsuno Y, Hirohashi S, et al. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene. 1992;7:451-457.
39. Mitsudomi T, Oyama T, Kusano T, et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:2018-2023.
40. Lohmann D, Pütz B, Reich U, et al. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol. 1993;142:907-915.
41. Levine AJ. The p53 tumour suppressorgene and product. In: Levine AJ, ed. Tumour Suppressor Genes, the Cell Cycle and Cancer. Cancer Surveys Vol. 12. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1992:59-79.
42. Reynolds SH, Anna CK, Brown KC, et al. Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci USA. 1991;8:1085-1089.
43. Slebos RJC, Hruban RH, Dalesio O, et al., Relationship between K-ras-oncogene activation and smoking in adenocarcinoma of the lung. J Natl Cancer Inst. 1991;83:1024-1027.
44. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer. 1993;72:432-438.
45. Biggs PJ, Warren W, Venitt S, et al. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis. 1993; 8:275-283.
46. Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations in non-small cell lung cancer in Japan. Associations between mutations and smoking. Cancer Res. 1992;52:734-736.
47. Westra WH, Offerhaus GJ, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol. 1993;17:213-220.
48. Pelkonen O, Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev. 1982;34:189-222.
49. Peltonen K, Dipple A. Polycyclic aromatic hydrocarbons: chemistry of DNA adduct formation. J Occup Med. 1995; 37(in press).
50. Phillips DH, Hewer A, Martin CN, et al. Correlation of DNA adduct levels in the human lung with cigarette smoking. Nature. 1988;336:790-792.
51. Phillips DH, Schoket B, Hewer A, et al. Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int J Cancer. 1990;46:569-576.
52. 32P-post-labelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis. 1991;12:1301-1305.
53. Alexandrov K, Rojas M, Geneste O, et al. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers’ lung: and AHH activity. Cancer Res. 1992; 52:6248-6253.
54. Eisenstadt E, Warren AJ, Porter J, et al. Carcinogenic epoxides of benzo[a] pyrene and cyclopenta[cd]pyrene induce base substitutions via specific transversions. Proc Natl Acad Sci USA. 1982;79:1945-1949.
55. Yang JL, Chen RH, Maher VM, et al. Kinds and location of mutations induced by (±)-7β,8α-dihydroxy-9α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in the coding region of the hypo-xanthine (guanine) phosphoriboxyl-transferase gene in diploid human fibroblasts. Carcinogenesis. 1991; 12:71-75.
56. Ronai ZA, Gradia S, Peterson LA, et al. G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosa-mino)-1 -(3-pyridyl)-1 -butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis. 1993; 14:2419-2422.
57. You M, Candrian U, Maronpot RR, et al. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA. 1989;86:3070-3074.
58. Mass MJ, Jeffers AJ, Ross JA, et al. Kiras oncogene mutations in tumors and DNA adducts formed by benz[j]acean-thrylene and benzo[a]pyrene in the lungs of strain A/J mice. Mol Carcinog. 1993;8:186-192.
59. 6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog. 1993;8:177-185.
60. Marion M-J, Froment O, Trépo C. Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog. 1991;4:450-454.
61. Taylor JA, Sandler DP, Bloomfield CD, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst. 1992; 84:1626-1632.
62. Hollstein M, Marion M-J, Lehman T, et al. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-ex-posed factory workers. Carcinogenesis. 1994;15:1-3.
63. Vähäkangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992;339:576-580.
64. Taylor JA, Watson MA, Devereux TR, et al. p53 mutation hotspot in radon-associated lung cancer. Lancet. 1994; 343:86-87.
65. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847-849.
66. 1 arrest and apoptosis. Cancer Res. 1994;54:1169-1174.
67. Vainio H, Husgafvel-Pursiainen K, Anttila S, et al. Interaction between smoking and asbestos in human lung adenocarcinoma: role of K-ras mutations. Environ Health Perspect. 1993; 101 (Suppl 3): 189-192.
68. Nuorva K, Mäkitaro R, Huhti E, et al. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med. 1994;150:528-533.
69. Karjalainen A, Anttila S, Vanhala E, et al. Asbestos exposure and the risk of lung cancer in a general urban population. Scand J Work Environ Health. 1994;20:243-250.
70. Vainio H, Boffetta P. Asbestos and smoking in the etiology of lung cancer: mechanisms of the combined effect. Scand J Work Environ Health. 1994; 20:235-242.
71. Mossman BT. Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited. Br J Ind Med. 1993;50:673-676.
72. Takeuchi T, Morimoto K. Crocidolite asbestos increased 8-hydroxydeoxygu-anosine levels in cellular DNA of a human promyelocytic leukemia cell line, HL60. Carcinogenesis. 1944; 15: 635-639.
73. Jackson JH, Schraufstatter IU, Hyslop PA, et al. Role of oxidants in DNA damage: hydroxyl radical mediates the synergistic DNA damaging effect of asbestos and cigarette smoke. J Clin Invest. 1987;80:1090-1095.
74. Reid TM, Loeb LA. Mutagenic specificity of oxygen radicals produced by human leukemia cells. Cancer Res. 1992;52:1082-1086.
75. Antman K, Aisner J, eds. Asbestos-Related Malignancy. London: Grune & Stratton; 1987.
76. Cote RJ, Jhanwar SC, Novick S, et al. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 1991;51:5410-5416.
77. Metcalf RA, Welsh JA, Bennett WP, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992;52:2610-2615.
78. Ridanpää M, Husgafvel-Pursiainen K. Denaturing gradient gel electrophoresis (DGGE) assay for K-ras and N-ras genes: detection of K-ras point mutations in human lung tumour DNA. Hum Mol Genet. 1993;2:639-644.
79. Rideout III WM, Coetzee GA, Olumi AF, et al. 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990;249:1288-1290.
80. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA. 1990;87:9958-9961.
81. Esteve A, Lehman T, Jiang W, et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog. 1993;8:306-311.
82. Kishimoto Y, Murakami Y, Shiraishi M, et al. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992;52:4799-4804.
83. Ryberg D, Kure E, Lystad S, et al. p53-Mutationsin lungtumors. Relationship to putative susceptibility markers for cancer. Cancer Res. 1993;54: 1551-1555.
84. Spruck CH, Rideout WM III, Olumi AF. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res. 1993;53: 1162-1166.
85. Williamson MP, Elder PA, Knowles MA. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer. 1994;9:108-118.
86. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992;52:6079-6082.
87. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 1992;7:1989-1997.
88. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994;54:1634-1637.
89. Bennet WP, Hollstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 1992;52:6092-6097.
90. Hruban RH, van der Riet P, Erozan YS, et al. Molecular biology and the early detection of carcinoma of the bladder—the case of Hubert H. Humphrey. N Engl J Med. 1994;330:1276-1278.
91. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52:4828-4831.
92. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993; 53: 2846-2851.
93. Knudson AG, Jr. Overview: genes that predispose to cancer. Mutat Res. 1991;247:185-190.
94. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991;51:3075-3079.
95. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561.
96. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993; 260:812-816.
97. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260: 816-819.
98. Merlo A, Mabry M, Gabrielson E, et al. Frequent microsatellite instability in primary small cell lung cancer. Cancer Res. 1994;54:2098-2101.
99. Shridhar V, Siegfried J, Hunt J, et al. Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res. 1994;54: 2084-2087.
100. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
101. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1993;368:753-756.
102. Merlo A, Gabrielson E, Askin F, et al. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res. 1994;54:640-642.